neurix.ch

What It Is

Neurix SA is a neuroscience and bioengineering services company based in Geneva, Switzerland. Founded in 2011, it originated from the University of Geneva. According to the website, its core offering is not traditional SaaS or enterprise software, but in vitro human iPSC-derived neural cell and 3D organoid models for drug discovery, neurotherapy research, and preclinical validation.

Core Capabilities

Neurix’s services cover glioblastoma invasion models, blood-brain barrier models, Alzheimer’s disease models, Parkinson’s disease models, and customized services. Its technical approach includes iPSC differentiation, 3D neural tissue/organoids, spheroid generation, 2D/3D imaging, immunohistochemistry/immunofluorescence, fluorescence assays, flow cytometry, as well as genomics and proteomics analysis. The website also highlights high-throughput drug screening, lead compound validation, short- and long-term compound testing, and the ability to customize disease models and assay methods for clients.

Pricing and Delivery

The website does not disclose packages, pricing, free trials, or standardized subscription models. Delivery is closer to a project-based CRO/research service model: first discussing research objectives, then customizing models, followed by model validation, drug or therapy testing, and finally data analysis and reporting. The process mentions approximately 2–3 weeks for model development, up to 2–3 months for validation, about 1 month for testing, and around 1–2 weeks for reporting. Actual timelines should depend on project complexity.

Pros and Cons

Its strengths lie in its focus on human iPSCs and highly physiologically relevant 3D models, which can reduce reliance on animal experiments and early-stage human trials. Its disease scenarios are clearly defined, making it particularly suitable for brain disorders, neurodegenerative diseases, and blood-brain barrier research. The team’s background spans neuroscience, stem cells, drug discovery, and business development, and the site also mentions support from European research funding. The main limitation is limited transparency: there is no visible information on pricing, case data, quality systems, data security compliance, APIs, permission management, cloud deployment, or third-party software integrations, so it cannot be evaluated as a typical SaaS platform.

Who It’s For and Access from China

Neurix is better suited for pharmaceutical companies, biotech firms, university laboratories, and preclinical R&D teams, especially organizations that need customized human brain disease models, compound screening, or mechanism-of-action studies. Access from China cannot be determined from the main content; its services are delivered in Switzerland, and cross-border collaboration may require further confirmation of sample, data, and compliance requirements.